The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.

Novo Nordisk said it expects weaker sales growth of its popular weight-loss drug Wegovy due to competition from copycat drugs ...

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the ...

Novo now expects 2025 sales growth of 8%-14% in local currencies, down from its previous 13-21% range. It also lowered its ...

In a surprise double announcement Tuesday, Novo reduced sales guidance by 5%—attributing the change to slowed growth of its ...

Novo Nordisk has appointed Maziar Mike Doustdar as President and CEO, effective August 7, 2025. Doustdar succeeds Lars ...

Professor Lene Oddershede Chief Scientific Officer, Planetary Science & Technology at the Novo Nordisk Foundation talks about the applications of quantum computing at the tech disruptors podcast. She ...

Novo Nordisk has an estimated 62% market share of the GLP-1 agonist market, with archrival Eli Lilly accounting for another 35%. Investors are looking ahead to next-generation drugs that could ...

The move comes after Novo Nordisk’s share price fell 50% over the last 12 months, and amid growing pressure from the powerful Novo Nordisk Foundation, which controls the company’s voting majority.

A version of this article appears in print on May 17, 2025, Section B, Page 5 of the New York edition with the headline: Novo Nordisk, Its Stock Falling and Competition Rising, Will Replace Its C ...